Personalis at 2022 Neoantigen Based Therapies Summit US: OCT 25-26, 2022


Christelle Johnson

Christelle Johnson, PhD
Manager, Field Applications Scientist
Personalis, Inc.

OCT 25, 11 AM ET  

Personalis NeXT Platform: A Comprehensive Platform for Tissue and Plasma Profiling to Enable Personalized Medicine

  • ImmunoID NeXT enables tumor tissue-based immunogenomics profiling, accurate assessment of mutational landscape and putative neoantigens from analytically-validated exome and transcriptome assays, state-of-the-art neoantigen presentation and binding predictions built upon high quality immunopeptidomics training data, and multiple other emerging biomarkers, all from a single sample
  • In parallel, NeXT Personal is an ultrasensitive tumor-informed plasma-based assay, designed to detect molecular residual disease and cancer recurrence at earlier timepoints, with simultaneous longitudinal variant tracking for additional insight into disease progression

Connect with us at 2022 Neoantigen Based Therapies Summit US